# US 2022/0064106 A1 · Nitric oxide donors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064106 A1
- Document ID: US20220064106A1
- Status: Published application
- Kind: A1
- Application number: 17/474,637
- Filed: 2021-09-14
- Published: 2022-03-03
- Earliest claimed: 2016-06-22
- Assignees: MedChem Partners, LLC
- Applicants: MedChem Partners, LLC
- Inventors: Steven RIESINGER; Tsvetelina LAZAROVA; Zinadia RIBKOVSKAIA
- Web page: https://patentgrep.com/patent/US20220064106A1

## CPC

- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- C07C 245/24: Chains of only three nitrogen atoms, e.g. diazoamines
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07C 69/63: of saturated acids
- C07C 69/65: of unsaturated acids
- C07C 243/06: N-nitroso-amines
- C07C 243/42: Hydrazines having nitrogen atoms of hydrazine groups further singly-bound to hetero atoms
- C07C 403/20: having side-chains substituted by carboxyl groups {or halides, anhydrides, or (thio)esters thereof}
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/50: Nitrogen atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K 31/231: having one or two double bonds
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides, in part a novel class of nonoate compounds which exhibit nitric oxide releasing activity and their pharmaceutically acceptable salts, esters and prodrugs. The compounds release nitric oxide upon activation by contact with plasma. The present invention also relates to the use of the disclosed compounds to deliver nitric oxide to treat disorders arising from nitric oxide dysregulation.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

A composition comprising a compound represented by the Formula I:
or a pharmaceutically acceptable salt, ester or prodrug thereof, where:
X is CH2, m is 1;
R is alkyl, preferably having from 1 to 6 carbon atoms;
R1 is alkyl, preferably having from 1 to 6 carbon atoms;
or R and R1 taken together are carbon atoms to form a 5-7 member heterocyclic ring, said 5- 7 member heterocyclic ring being optionally substituted with —CH2OH;
A is —B(OR2)(OR3), —(Y)p—C(═O)-R4,
1,3-dioxoisoindolin-2-yl, heterocycloalkyl, or a lipid, where
Y is —CH2— and p is 0 or 1;
q is 0, 1 or 2;
R2 and R3 are the same or different and are alkyl, or aryl, optionally substituted with —OH;
R4 is alkyl (optionally substituted with —NH2), alkenyl, heteroalkyl (optionally substituted with one or more moieties independently selected from oxo, halo and
aryl, N-alkyl, N-aryl, O-alkyl or O-aryl; and with the proviso that R4 is not methyl and Z is alkyl, aryl, N-alkyl, N-aryl, O-alkyl or O-aryl.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the compound is selected from:

### Claim 58

A composition comprising a compound selected from:
or a pharmaceutically acceptable salt, ester or prodrug thereof.

### Claim 59 (depends on 56)

The compound of claim 56, wherein the compound is capable of releasing nitric oxide under physiological conditions.

### Claim 60 (depends on 56)

A pharmaceutical composition, comprising the compound of claim 56 and a pharmaceutically acceptable carrier or excipient.

### Claim 61 (depends on 56)

A method for treating a disorder of nitric oxide dysregulation comprising administering a therapeutically effective amount of the compound of claim 56 or a pharmaceutically acceptable salt, ester or prodrug thereof to a patient in need thereof.

### Claim 62 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is one or more of a cardiovascular disorder, vasodilation, and erectile dysfunction.

### Claim 63 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is a cardiovascular disorder.

### Claim 64 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is a metabolic-related disorder.

### Claim 65 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is a pulmonary disorder.

### Claim 66 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is an intraocular pressure-associated disorder.

### Claim 67 (depends on 66)

The method of claim 66, wherein the intraocular pressure-associated disorder is glaucoma.

### Claim 68 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is ischemia.

### Claim 69 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is infection, and optionally wherein the infection is bacterial infection.

### Claim 70 (depends on 61)

The method of claim 61, wherein the disorder of nitric oxide dysregulation is cancer.

### Claim 71 (depends on 56)

A method for enhancing or stimulating wound healing, comprising administering a therapeutically effective amount of the compound of claim 56 or a pharmaceutically acceptable salt, ester or prodrug thereof to a patient in need thereof.
